XML 118 R103.htm IDEA: XBRL DOCUMENT
v3.22.4

NET SALES - Disaggregation of Revenue (Details) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | $ 15,113 | $ 12,784 | $ 11,673
U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 7,223 | 5,180 | 4,878
International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 7,890 | 7,604 | 6,795
Renal Care |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 3,748 | 3,900 | 3,757
Renal Care | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 945 | 890 | 848
Renal Care | International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 2,803 | 3,010 | 2,909
Medication Delivery |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 2,886 | 2,880 | 2,691
Medication Delivery | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 1,889 | 1,859 | 1,738
Medication Delivery | International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 997 | 1,021 | 953
Pharmaceuticals |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 2,126 | 2,291 | 2,098
Pharmaceuticals | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 682 | 753 | 849
Pharmaceuticals | International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 1,444 | 1,538 | 1,249
Clinical Nutrition |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 931 | 964 | 910
Clinical Nutrition | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 352 | 343 | 330
Clinical Nutrition | International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 579 | 621 | 580
Advanced Surgery |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 998 | 977 | 886
Advanced Surgery | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 574 | 545 | 516
Advanced Surgery | International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 424 | 432 | 370
Acute Therapies |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 701 | 782 | 740
Acute Therapies | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 241 | 287 | 286
Acute Therapies | International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 460 | 495 | 454
BioPharma Solutions |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 644 | 669 | 486
BioPharma Solutions | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 305 | 273 | 234
BioPharma Solutions | International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 339 | 396 | 252
Patient support systems |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 1,487 | 115 | 0
Patient support systems | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 1,150 | 86 | 0
Patient support systems | International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 337 | 29 | 0
Front line care |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 1,148 | 70 | 0
Front line care | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 840 | 51 | 0
Front line care | International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 308 | 19 | 0
Surgical solutions |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 304 | 27 | 0
Surgical solutions | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 145 | 12 | 0
Surgical solutions | International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 159 | 15 | 0
Other |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 140 | 109 | 105
Other | U.S. |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | 100 | 81 | 77
Other | International |  |  |
Disaggregation of Revenue [Line Items] |  |  |
Total net sales | $ 40 | $ 28 | $ 28

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_RenalCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_MedicationDeliveryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_PharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_ClinicalNutritionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_AdvancedSurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_AcuteTherapiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_BioPharmaSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_PatientSupportSystemsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_FrontLineCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_SurgicalSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bax_OtherProductOrServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |